Scott Alan Mccauley

TL;DR: Targeting LOXL2 with an inhibitory monoclonal antibody (AB0023) was efficacious in both primary and metastatic xenograft models of cancer, as well as in liver and lung fibrosis models and outperformed the small-molecule lysyl oxidase inhibitor β-aminoproprionitrile.

TL;DR: It is shown that selective inhibition of MMP9 did not induce musculoskeletal syndrome in a rat model, but did reduce disease severity in a dextran sodium sulfate-induced mouse model of ulcerative colitis, and that inhibition of either tumor- or stroma-derived M MP9 was sufficient to reduce primary tumor growth.

TL;DR: It is reported that pegilodecakin induces hallmarks of CD8+ T cell immunity in cancer patients, including elevation of interferon-γ and GranzymeB, expansion and activation of intratumoral CD8- T cells, and proliferation and expansion of LAG-3+ PD-1+ CD8 cells.

TL;DR: The results suggest that antibody allosteric modulators of enzymatic function represent a novel drug development strategy and, in the context of LOXL2, suggest that inhibitors such as these might be useful therapeutics in oncology, fibrosis, and inflammation.

TL;DR: In this article, the authors provide innovative methodology and related compositions and kits for preventing and treating various diseases associated with abnormal cell proliferation, angiogenesis and fibrosis, by using an inhibitor of processed forms of lysyl oxidase or lysy oxidase-like proteins, an inhibitor and a synergistic combination of a LOX or LOXL combined with other therapeutic agents, by contacting cells that are in an epithelial-mesenchymal transition state with a candidate agent and detecting a change in the EMT state of the cells.